|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.
Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Teva Pharmaceutical Industries Ltd. Here are 5 ETFs with the largest exposure to TEVA-US. Comparing the performance and risk of Teva Pharmaceutical Industries Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether the company will face a downgrade to high yield or whether it can find the "transformative deal" needed for a core generics comeback. Next year looks possible for recovery, but what of Teva's long-term revival?
Antares Pharma’s gross profit margins reached 45.0%, 57.0%, and 58.0% for fiscal 2016, fiscal 2015, and fiscal 2014, respectively.
Does the share price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. AnyoneRead More...
Billionaire Israel "Izzy" Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with volatile fire in the market: Teva Pharmaceutical (NYSE:TEVA) and Valeant Pharmaceuticals (NYSE:VRX). However, the hedge fund guru is doing away with almost all of ACADIA Pharmaceuticals (NASDAQ:ACAD), a stock that has attracted mostly bullish attention on the Street.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
In 3Q17, Novartis's (NVS) Entresto generated revenues of $128 million, compared with $53 million in 3Q16. Entresto witnessed a ~16% rise on a QoQ basis.
Europe has approved GlaxoSmithKline's (GSK.L) new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S). The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.
Announcement: Moody's: Health and Happiness' ratings unaffected by Swisse's buy-back of distribution rights. Global Credit Research- 16 Nov 2017. Hong Kong, November 16, 2017-- Moody's Investors Service ...
Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis. The decision by the European Commission to grant it marketing authorisation, announced by the company on Thursday, had been expected following a positive recommendation from the European Medicines Agency in September.
The Crown Prince of Abu Dhabi launched a fund with the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis, which leads to a condition known as elephantiasis.
Shares of generic and specialty drug producer Teva Pharmaceutical (TEVA) jumped 7% Wednesday afternoon as investors get more hopeful about the future. Jefferies analysts met with Teva executives in Israel including the head of research and development, and concluded in a fresh report today that new CEO Kare Schultz may discuss strategy with investors by the end of the year, to coincide with quarterly results. Jefferies analysts David Steinberg, Edward Chung and Anthony Baldor gleaned in meetings that cost cutting and asset sales are "on the table" for Teva, with $35 billion in debt, high leverage and weakening profitability over time.
New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.
VBI Vaccines, Inc. - Ordinary Shares (NASDAQ: VBIV ) will release results on three clinical trials in the first half of 2018, presenting certain investment opportunities of an uncertain nature. Some on ...
In support of the $675 million deal, Greg Bradley joined Foundation Consumer Healthcare as president and chief executive.
Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove themselves, before the Israeli pharma giant can make a comeback- at least in the eyes of Cantor analyst Louise Chen.
The CNBC IQ100 index beating the broader market over one year, up 22%. Today's leaders include GE, Teva pharma and Nike. The laggards Target, Johnson Controls and Mattel